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Abstract
Objective The aim of this study is to assess urine levels of
aripiprazole and metabolites among patients receiving steady-
state dosing of aripiprazole.
Methods One hundred fifty adults, judged compliant with a
stable aripiprazole regimen, had observed dosing for 5 con-
secutive days. Urine specimens, obtained on days 1, 4, and 5,
were analyzed for pH, creatinine, specific gravity, and for
aripiprazole, OPC3373, and dehydroaripiprazole. Linear re-
gression was used to assess the association between unadjust-
ed urine levels of each drug/metabolite and dose taken, and
linear stepwise multiple regression was performed to identify
variables that added to the explanation of the variance.
Results OPC3373 was found in 97 % of urine samples,
whereas unchanged aripiprazole and dehydroaripiprazole
were found in only 58 and 39 % of samples, respectively.
Variance in urine metabolite levels accounted for by medica-
tion dose was relatively low for each individual
drug/metabolite, r2 only 0.13 to 0.23. However, when
OPC3373 was adjusted for age, weight, sex, and urine creat-
inine values, the r2 improved to 0.63, and further improved to
0.70, when height, urine specific gravity, and the presence of
dehydroaripiprazole were added in a stepwise multiple regres-
sion model.
Conclusions Unadjusted urine levels of aripiprazole and me-
tabolites are not strongly related to aripiprazole dosing, how-
ever, accounting for key variables yields a strong relationship
between measurable urine parameters and dose taken. By
defining the expected range of adjusted urine levels for each
dose, the potential exists for a clinical test to identify partially
nonadherent individuals who would not have been identified
by conventional “present vs. absent” urine drug testing.
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Adherence to a medication regimen plays an important role in
maximizing outcomes for individuals with schizophrenia, de-
pression, and other mental health disorders (Valenstein et al.
2001; Velligan et al. 2003; Weiden and Glazer 1997). Medi-
cation plan adherence is poor across a wide variety of physical
and psychiatric conditions (Dolder et al. 2002; Grymonpre
et al. 1998; Haynes 1979; Velligan et al. 2003), and it is
especially poor in patients with schizophrenia (Velligan et al.
2003; Weiden and Glazer 1997; Lindenmayer et al. 2009). It
has been estimated that half of patients with schizoaffective
disorder and schizophrenia take less than 70 % of their pre-
scribed dose (Cramer and Rosenheck 1998). Poor adherence
(including partial adherence) has been found to be an inde-
pendent predictor of treatment discontinuation (Perkins et al.
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2008), as well as relapse, re-hospitalization, long-term func-
tional outcome, and suicide in patients with schizophrenia
(Llorca 2008). Although new generations of drugs, such as
aripiprazole, are becoming increasingly available with im-
proved side effect profiles, levels of adherence remain alarm-
ingly low (Grymonpre et al. 1998; Velligan et al.
2003). Over the last few decades, the literature has de-
scribed many possible explanations for the causes of poor
adherence and presented potential approaches to improving
compliance (Fenton et al. 1997; Oehl et al. 2000; Zygmunt
et al. 2002). Unfortunately, there has been remarkably little
agreement regarding an objective definition of adherence, or
how to measure it. Current techniques are either not accurate
enough, prone to error, or very difficult to perform in the
clinical setting. The most common method used to assess
adherence in the mental health population has been patient
self-report (Velligan et al. 2006, 2010). In a study by Velligan
et al. (2007) comparing patient self-report or physician assess-
ment of compliance with more objective measures, it was
shown that neither patients nor physicians were able to char-
acterize adherence accurately. The objective measures used in
the study were pharmacy fill rates of patients’ prescriptions,
pill counts, and electronic monitoring. Although more accu-
rate, these measures would probably not be easy to perform in
clinical practice for a variety of reasons (Byerly et al. 2007;
Farmer 1999). It has been a matter of debate whether serum
therapeutic drug monitoring (TDM), a more invasive method,
should be implemented in clinical practice (Hiemke et al.
2011). Serum TDM is a powerful tool for determination of
adherence for some antipsychotic medications. Despite in-
creasingly sophisticated methods to measure adherence, alter-
native objective tools could improve ascertainment (Sajatovic
et al. 2010). Once nonadherence is identified, proven strate-
gies to improve adherence can be employed (Velligan and
Sajatovic 2013). As with other therapies, urine drug testing
(UDT) for antipsychotic medication therapy is commercially
available to test for the presence or absence of the drug. The
limitations of traditional qualitative UDT have been noted
(Nafziger and Bertino 2009). Detection of partial
nonadherence, which is likely more common than taking no
doses, is especially challenging since a positive urine test may
occur even with substantial, clinically relevant partial
nonadherence. Quantitative UDT has been in use for some
time primarily for pain medication management, where lower
than expected urine drug levels is a factor in evaluating not
only partial nonadherence but also diversion or hoarding of
medication, and higher than expected levels can be used to
assess overdosing which can lead to hospitalization and
death. The goal of the current study was to assess the
relationship between aripiprazole dose taken and quantitative
urine levels of aripiprazole and its metabolites, among patients
receiving steady-state dosing of aripiprazole. Importantly, we
also wished to determine if the strength of this relationship
would be improved if we accounted for variables that have the
potential to impact on urine levels of aripiprazole and its
metabolites. It is hoped that these data may lead to a quanti-
tative UDT that can help clinicians understand patient com-
pliance, at a level beyond what can be achieved by simple
present vs. absent testing, and become an efficient, clinically
and cost-effective tool for physicians who treat these patients.
Methods
Study population
This prospective study was conducted from 03/11/2013 to 12/
17/2013 at Carolina Behavioral Care in Durham,
Hillsborough and Pinehurst NC and at Georgia Regents Uni-
versity in Augusta, GA. IRB approval was obtained for all
study sites.
The study population consisted of 150 adult outpatients
who, in the clinical judgment of the study staff, were compli-
ant with a stable once daily aripiprazole regimen for 2 weeks
prior to enrollment. Recruitment was stratified with a goal of
enrolling between 30 and 60 subjects in each of the following
three ranges of aripiprazole dosing: (a) 2–5 mg, (b) 10–15mg,
and (c) 20–30 mg. Exclusion criteria were as follows: known
to be pregnant or breastfeeding, known significant hepatic or
renal impairment, a significant medical condition that would
interfere with study participation, or ingestion of certain con-
comitant medications and foods over the past 2 weeks that
interfere with metabolism of aripiprazole.
After providing informed consent, subjects underwent an
abbreviated physical exam and provided a medical and med-
ication history. On each of five consecutive days, all subjects
were required to come to the clinic, where study staff observed
as each subject took her/his prescribed dose of aripiprazole.
On study days 1, 4, and 5, the subjects provided a pre-dose
urine specimen. On study day 5, subjects were evaluated for
disease severity using the Clinical Global Impression (CGI)
(Guy 1976). All urine samples were collected just prior to
drug administration, near the nadir of serum/urine drug levels
(median time between prior dose and urine sample 24.1 h,
extremes 17.9 and 30.7 h; and median time between urine
sample and next dose was 5 min, extremes 1 and 109min. The
average time of dosing was 11:30 a.m. (extremes 7:00 a.m.
and 1:00 p.m.).
Laboratory methods
Upon receipt at Ameritox, Ltd. (Greensboro, NC), urine spec-
imens underwent immediate specimen validity tests for pH,
creatinine, and specific gravity. This was followed by confir-
matory analysis for aripiprazole metabolites, OPC3373 and
dehydroaripiprazole, and parent drug, aripiprazole. The
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authentic specimens were prepared by fivefold dilution with
deionized water acidified with formic acid, and methanolic
internal standard solution. Urine samples were analyzed on a
Waters Acquity UPLC TQMS (Waters, Milford, MA) using a
Waters Acquity UPLC® CSH™ Phenyl-Hexyl, LC analytical
column (2.1 mm×50 mm, 1.7 μm). The internal standard
solution contained aripiprazole D8 and clozapine D4. Subject
samples were not hydrolyzed prior to analysis. The column
temperature was held at 50 °C and the injection volume was
5 μL. The mobile phase consisted of 2 mM ammonium
acetate with 0.1 % formic acid (solvent A) and methanol
(solvent B). Analytes were separated by gradient elution in a
3.6 min total cycle time. Mass spectral data was acquired in
positive electrospray ionization mode with two selected tran-
sition ions for all analytes and internal standards. The source
temperature was 150 °C and desolvation temperature was
600 °C. The desolvation gas was nitrogen and the collision
gas was argon with flow rates of 1200 L/h and 0.20 mL/min,
respectively. Cone gas flow was 100 L/h. Multipoint calibra-
tion curves were prepared in normal human urine in the
established linear range for each analyte and at the same
dilution as specimens. The limits of quantitation/detection
(LOQ/D) we r e 5 ng /mL fo r a r i p i p r a zo l e and
dehydroaripiprazole and 25 ng/mL for OPC3373. Upper
limits of linearity and carryover were 5000 ng/mL for all
compounds. Inter- and intra-assay precision did not exceed
11.0 % coefficient of variation, and accuracy was within
16.6 % of target concentrations for all compounds.
Statistical methods
The proportion of all urine samples for which each metabolite
was detectable was tabulated to verify data reported previous-
ly (Dretchen et al. 2013) that the OPC3373 metabolite was the
only metabolite that was consistently detectable in subjects
taking aripiprazole. Based on this observation, the urine
OPC3373 value was the primary factor used in equation
development.
Based on first pharmacokinetic principles, an equation was
developed to calculate an adjusted OPC3373 level in an
attempt to account for individual physiological and anatomic
differences between the study subjects. The adjuster equation
used the raw urine OPC3373 metabolite concentration, age,
weight, sex, and urine creatinine values.
When calculating the adjusted OPC3373 level, if a subject
had an OPC3373 concentration below the LOQ (i.e., 25 ng/
mL), a value of 12.5 ng/mL (i.e., halfway between zero and
25) was used for the adjustment, since it is not possible to
calculate a natural log (Ln) for zero.
Correlation coefficients were calculated for the adjusted
OPC3373 levels for days 1 vs. 4, 1 vs. 5, and 4 vs. 5 to assess
the stability of values across study days and to determine the
suitability of pooling results from urine samples obtained on
the different study days. Note that the first 20 subjects enrolled
in this study also had serum aripiprazole levels obtained on
days 1 and 5, and based on these data, we have previously
reported that stability in serum levels from day 1 to 5 was
consistent with the subjects being adherent to their prescribed
dosing at study entry and at steady state during the period of
observed dosing.
Table 1 Characteristics of subjects
All subjects
Characteristic N=150
Male, n (%) 61 (34.0)





Hispanic, n (%) 3 (2.0)








HS graduate 40 (26.7)
Some college 55 (36.7)
College graduate 22 (14.7)
Employment status, n (%)
Unemployed 39 (26.0)
Part-time employment 21 (14.0)








Current psychiatric diagnosisa, n (%)
Schizophrenia 24 (16.0)
Bipolar disorder 56 (37.3)
Major depressive disorder 63 (41.3)
Other 52 (34.7)
Clinical global impression, mean (SD) 2.6 (1.1)
Body mass index, mean (SD) 31.8 (8.4)
a Subjects may have had more than one psychiatric diagnosis
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When pooling results, multiple results from the same sub-
ject were weighted such that there was an equal contribution
to the analysis from each subject (i.e., if a subject contributed
two samples, each received a weight of 0.5, whereas if a
subject contributed only one sample, the sample received a
weight of 1.0). Linear regression methods were used to assess
the association between unadjusted urine levels of each
drug/metabolite and observed dose taken.
A linear stepwise multiple regression was performed using
the natural log of the dose as the dependent variable and a
number of candidate independent variables in an attempt to
identify those that significantly added to the explanation of the
variance. The candidate variables included adjusted urine
OPC3373 levels, presence vs. absence of urine aripiprazole
and dehydroaripiprazole, urine creatinine, urine specific gravity,
urine pH, age, sex, race, smoking category (never, past, or
current) height, weight, and time between urine test void and
prior void. Variables were added to the model as long as the
addition of that variable added to the r2 at p<0.15. In an attempt
to create a final parsimonious model, only variables that im-
proved the r2 by >0.015 were included in the final model.
Results
Study population
The characteristics of the 150 subjects enrolled in the study are
shown in Table 1. Approximately two-thirds of the subjects
were female, and the mean age was 44.6 years. The most
common psychiatric diagnoses were major depressive disor-
der (41.3 %) and bipolar disorder (37.3 %). Only 16.0 % of
subjects had schizophrenia. Consistent with these diagnoses,
the mean illness severity on the CGI was 2.6.
The distribution of aripiprazole doses taken by subjects is
shown in Fig. 1. The stratified enrollment strategy resulted in
61 subjects in the low-dose stratum (2–5 mg), 60 in the
middle-dose stratum (10–15 mg), and 29 in the higher dose
stratum (20–30 mg).
Analyses of each metabolite in urine samples
Six urine samples from two subjects (one taking a dose of
2 mg, and one taking a dose of 5 mg) were excluded from
analyses because the subjects were found to be ineligible
following enrollment as they were taking excluded medica-
tions. Two additional subjects did not provide all three urine
samples; one provided a urine sample only on day 1, the other
only on days 1 and 4, leaving a total of 441 urine samples
available from 148 subjects (148 day 1 samples, 147 day 4
samples, and 146 day 5 samples).
OPC3373 was the metabolite most consistently present in
urine samples (Fig. 2). OPC3373 was found in (97 %) urine
samples overall, ranging from 92 % of samples from individ-
uals taking 2 mg to 100% of samples from those taking 20mg
or greater. Whereas, unchanged aripiprazole and
dehydroaripiprazole were found in only 58 and 39 % of urine
samples, respectively, with relatively low rates of detection
even at higher doses.
There was high correlation between adjusted urine
OPC3373 levels in urine samples obtained on days 1, 4, and
5. The strongest correlation was between days 4 and 5 (R=
0.91), with the correlations between days 1 and 4 and 1 and 5,
being only slightly lower (0.84 and 0.80), respectively
(Fig. 3). These results suggested that the goal of enrolling
Fig. 1 Number of subjects receiving each aripiprazole dose (n=150)
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adherent individuals on stable dosing was achieved, with a
very small number of lower adherent individuals, likely ac-
counting for the slightly lower correlation between the day 1
levels vs. day 5, compared to the day 4 levels vs. day 5. Based
on the high correlation between days 4 and 5 adjusted urine
OPC3373 levels, days 4 and 5 urines were pooled, so that
there were 293 samples used in subsequent analyses.
Relationship between unadjusted urine metabolites
and aripiprazole dose
The relationship between each individual drug/metabolite and
aripiprazole dose taken is shown in Fig. 4a–c. The variance in
urine metabolite levels that is accounted for by medication
dose, as measured by the r2, is relatively low for each indi-
vidual drug/metabolite, ranging from only 0.13 for
aripiprazole to 0.23 for OPC3373.
Relationship between adjusted urine OPC3373 plus other
variables and aripiprazole dose
The results of the stepwise multiple regression analyses are
shown in Table 2. Adjusted OPC3373 was the most important
single variable with an r2 of 0.63. Five other variables met the
criteria of p<0.15 for inclusion in the stepwise regression, with
height adding an additional r2 of 0.03 to the model, and urine
specific gravity and the presence of dehydroaripiprazole in the
urine, each adding an additional 0.02 to the model. Although,
race and time between urine test void and last prior void, both
met our initial criteria for inclusion in the model, each added
only 0.01 or less to the r2 value, and in the interest of having a
reasonably parsimonious model, we elected to use only the
variables that contributed at least 0.02 to the r2 in the final model
which is illustrated in Fig. 4d, with a final model r2 of 0.70.
Discussion
This study has shown that while unadjusted urine levels of
aripiprazole and two of its metabolites are not strongly related
to aripiprazole dosing, when multiple drug/metabolites are
taken into account and when one accounts for physiologic
variables that may impact on the urine metabolite levels, there
is a strong relationship between measurable urine parameters
and dose taken. This offers the potential for clinicians to
identify individuals who appear adherent based on standard
present vs. absent testing, but who have urine results that are
lower than expected for their prescribed dose.
We have previously reported, based on the first 20 subjects
enrolled in this study (Dretchen et al. 2013), that at doses of 2–
5 mg, OPC3373 was the most consistently identified urine
drug/metabolite of aripiprazole, being found in 93 % of sam-
ples, compared to 50 and 8 % for urine aripiprazole and
dehydroaripiprazole, respectively. These findings have been
confirmed and expanded with the full sample of 150 subjects
to show that overall OPC3373 was detectable in 97 % of
samples (ranging from 92 % at 2 mg to 100 % at doses
>15 mg), whereas urine aripiprazole and dehydroaripiprazole
were detectable less frequently, even at high doses (percent
detected ranging from 33 % at 2 mg to 80 % at 30 mg for
aripiprazole, and 2 % at 2 mg to 93 % at 30 mg for
dehydroaripiprazole). It should be noted, however, that we
enrolled only a small number of individuals, with severe
disease (e.g., schizophrenia), who were taking aripiprazole
doses of >20 mg, and therefore have a limited ability to draw
conclusions about this higher dose range.
In humans, aripiprazole is primarily converted in the liver
to two major metabolites. It undergoes dehydrogenation to
form dehydroaripiprazole, which is pharmacologically active.
It is also converted through dealkylation to form the inactive
compound OPC3373. These pathways involve both CYP2D6
and CYP3A4 enzymatic pathways. Less than 1 % of
aripiprazole is excreted unchanged in the urine. Blood levels
Fig. 2 Percent of samples greater than the limits of detection for each
metabolite by dose (note that data for 2.5 and 25 mg doses were omitted
from the figure due to the small number of samples at those doses)
Fig. 3 Correlation between
adjusted urine OPC3373 levels
across dosing days
Psychopharmacology (2014) 231:4421–4428 4425
of aripiprazole have been shown to be increased in individuals
with hepatic impairment (Mallikaarjun et al. 2008). As ex-
pected, the blood levels of the dehydroaripiprazole derivative
are reduced in liver toxicity (Mallikaarjun et al. 2008). Results
of the same study revealed that the blood levels of aripiprazole
were increased during renal impairment (Mallikaarjun et al.
2008). The mean elimination half-lives for aripiprazole and its
other active metabolites are 75 and approximately 94 h, re-
spectively. Steady-state serum levels are achieved in 14 days
of dosing (Otsuka America Pharmaceutical, Inc. 2014). This
study enrolled subjects that were judged to be adherent to a
stable dosing regimen and utilized a 5-day observed dosing
period to improve confidence that we knew the aripiprazole
dose was actually taken by the subject. Althoughwe cannot be
certain that subjects were indeed always adherent prior to
enrollment or that they did not take additional aripiprazole at
home during the observed dosing days, the high correlation
between the days 1, 4, and 5 samples suggests that subjects
were indeed on stable doses and, especially by day 4 of
observed dosing, were at steady state. In the first 20 subjects
of this study, who had days 1 and 5 serum aripiprazole levels,
steady-state dosing was also supported by stability of serum
Fig. 4 a Unadjusted urine aripiprazole vs. ln dose. b Unadjusted urine dehydroaripiprazole vs. ln dose. c Unadjusted urine OPC3373 vs. ln dose. d
Predicted ln dose from multiple regression equation vs. ln dose
Table 2 Results of stepwise multiple linear regression model: partial r2
and model r2 for natural log of aripiprazole dose
Independent variable Partial r2 Model r2 P value
Adjusted urine OPC3373 0.63 0.63 <0.0001
Height (inches) 0.03 0.66 <0.0001
Urine specific gravity 0.02 0.68 0.0001
Dehydroaripiprazole present in urine 0.02 0.70 <0.0001
Black race 0.01 0.71 0.0015




aripiprazole levels over the 5-day observed dosing period
(Dretchen et al. 2013).
Our findings regarding unadjusted levels of aripiprazole in
urine are not dissimilar to the findings regarding unadjusted
levels of clozapine in blood. Although the utility of measuring
clozapine levels in blood is established as a means of TDM, it
is known that there is substantial inter- and intraindividual
variability because of variability of CYP-450 composition as
well as changing daily caffeine intake and smoking; clinicians
must incorporate these additional factors into dosing decisions.
The importance of understanding adherence clinically can-
not be overstated. Of primary importance is achieving an effec-
tive dose of medication to alleviate patients’ mental health
symptoms. When adherence with medication is unknown, it
is difficult for the physician to know when to adjust the dose or
to change to another drug. Failure to detect nonadherence using
insensitive methods may lead to delayed identification and
offers the risk of relapse (Velligan and Sajatovic 2013).
Monitoring medication adherence by conventional “pres-
ent vs. absent” urine drug testing is limited to the identification
of individuals whose urine drug levels are below the LOD
(e.g., 5 ng/mL for aripiprazole and dehydroaripiprazole;
25 ng/mL for OPC3373). Our data demonstrate that such
testing using unadjusted aripiprazole and dehydroaripiprazole
may often provide false negative results, since even during
observed dosing, individuals commonly have urine concen-
trations for these metabolites that are below the LOD.
OPC3373 is clearly the most appropriate metabolite for
assessment of adherence, since it was almost always above
the LOD in these subjects who had observed dosing. Howev-
er, although OPC3373 performed well for assessment of
“present vs. absent” testing, with few false negatives, the
unadjusted OPC3373 levels did not change very much as the
dose of aripiprazole changed. In contrast, with the adjustment
algorithm developed in this study, the association between
urine levels and dose was much greater, such that it is possible
to identify a range of values for which the urine value would
be above the LOD (i.e., present), but be clearly below the
expected level for a specified prescribed dose. Therefore, by
defining the expected range of the adjusted urine levels for
each dose, the potential exists for a clinical test that would
identify partially nonadherent individuals who would not have
been identified by conventional “present vs. absent” urine
drug testing. This distinction would likely have substantial
clinical utility, as intermittent adherence is an important clin-
ical obstacle to appropriate pharmacologic treatment with
antipsychotic medications.
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